The FDA is set to convene an oncology advisory committee meeting after a long hiatus, with AstraZeneca drugs among the primary topics. The agenda centers on applications spanning HR+/HER2- locally advanced or metastatic breast cancer and metastatic castration-resistant prostate cancer. The meeting follows the FDA’s broader push to speed up review and reflects how late-stage oncology submissions are increasingly being stress-tested by regulators before decisions. For AstraZeneca, ODAC scrutiny also comes at a time when several pipeline programs have been under pressure. Clinicians and trial sponsors will be watching how the agency evaluates the benefit-risk profile, endpoints, and any safety flags that could influence labeling outcomes.